ImmunogenX Acquired by First Wave BioPharma

2 minute read | April.10.2024

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, has acquired ImmunogenX in an all-stock transaction.

Orrick represented ImmunogenX.


ImmunogenX, Inc. is a clinical-stage company founded in 2013 and supported by a team of world renowned scientists and collaborators. ImmunogenX was formed to address critical needs for individuals with suspected or diagnosed celiac disease.

First Wave BioPharma specializes in developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company is headquartered in Boca Raton, Florida.


The combined company will focus on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.

First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval. First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.

“Completion of the acquisition of ImmunogenX and the addition of latiglutenase to our clinical pipeline is a transformative event for First Wave BioPharma as it provides our company with a Phase 3-ready asset in a multibillion-dollar GI market – celiac disease – for which no approved pharmacologic treatment currently exists,” First Wave CEO James Sapirstein said in a statement.


David Schulman led the Orrick team that advised ImmunogenX. The team also included Audrey Schricker, Josh Steiman, Lorenzo Lista and Tiffany Chiu Leung.


First Wave BioPharma news release


Read More Orrick Client Results